

Research Article



Prevalence, Antifungal Susceptibility, and Biofilm-Forming Ability of Candida Species from Clinical Samples

Mahdi Mohammadi ¹, Mohammad Hassan Namaei ², Mostafa Ashrafipour ³, Mohammad Amin Abdolahi Ziaaldini ⁴, Fatemeh Nikoomanesh * ⁵

¹ Student Research Committee, Birjand University of Medical University, Birjand, Iran.

² Department of Laboratory Sciences, Faculty of Paramedical and Rehabilitation Sciences, Mashhad University of Medical Sciences, Mashhad, Iran.

³ Department of Parasitology and Mycology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

⁴ Student Research Committee, Birjand University of Medical University, Birjand, Iran.

⁵ Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

ABSTRACT

Received: 2026/01/04

Revised: 2026/06/12

Accepted: 2026/06/20

Introduction: Candida species, as opportunistic fungal pathogens, can form biofilms on biotic and abiotic surfaces, leading to resistance to current antifungals used in the treatment of candidiasis. This study aimed to identify Candida species from clinical samples and to assess antifungal susceptibility patterns and biofilm-forming ability.

Objectives: This study aimed to identify different Candida species from clinical samples and to assess the antifungal susceptibility patterns and biofilm formation ability.

Methods: In this study, 100 Candida isolates were obtained from various clinical samples (blood, urine, body fluids, etc.) by culturing. Antifungal susceptibility assays for Candida isolates were performed using the broth microdilution technique in accordance with the Clinical and Laboratory Standards Institute M27-A3/S4 guidelines. Biofilm formation was measured by the colorimetric microtiter method.

Results: Candida albicans (48%) was the most common Candida species identified, followed by C. glabrata (34%), C. dubliniensis (9%), C. tropicalis (5%), C. parapsilosis (1%), C. krusei (1%), and two mixed colonies were identified. The antifungal susceptibility pattern shows that Candida isolates exhibit varying susceptibilities. C. albicans was 100% susceptible to amphotericin B, whereas C. glabrata was 70.58% resistant to amphotericin B. The Candida parapsilosis isolate was susceptible to all antifungals. According to the results, Candida isolates have a moderate ability to form biofilms.

Conclusions: Therefore, periodic monitoring of Candida species prevalence and antifungal susceptibility patterns necessitates selecting the appropriate therapeutic protocol, as well as the development of novel antifungal compounds and treatment strategies.

Keywords: Antifungal, Biofilm formation, Candidiasis, Drug resistance

Corresponding Author: Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.

Email: fateme.nikoomanesh@bums.ac.ir



Copyright Policy: This open-access journal is available under the Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0)

International License, which allows for the copying and redistribution of the material only for noncommercial purposes, provided that the original work is properly cited.

How to Cite: Mohammadi M, Namaei M H, Ashrafipour M, Abdolahi Ziaaldini M A, Nikoomanesh F. Prevalence, Antifungal Susceptibility, and Biofilm-Forming Ability of Candida Species from Clinical Samples. Mod Care J 2026; 23 (2): 18-25. <https://doi.org/10.21859/ModCareJ.23.2.18>

1. Introduction

Candidiasis is an opportunistic fungal infection caused by *Candida* species, which normally inhabit the mucosal membranes of the mouth, gastrointestinal tract, and genital tract. Among *Candida* spp., *C. albicans* was the most identified and prevalent, followed by *C. glabrata*, *C. lusitaniae*, *C. parapsilosis*, *C. kefyr*, *C. famata*, *C. africana*, and *C. orthopsilosis*, in descending order of frequency (1,2). On the other hand, *Candida albicans* is identified as the most prevalent causative agent of candidiasis. In recent years, the prevalence of non-*albicans* species has increased significantly. Risk factors for candidiasis include the use of broad-spectrum antibiotics or steroids, prolonged intensive care unit (ICU) stays, central venous catheter placement, organ transplantation, chemotherapy or radiotherapy, mechanical ventilation (invasive or noninvasive), and diabetes (3-5).

Nowadays, emerging resistant species to first-line antifungal drugs (such as echinocandins and azoles) are leading to therapeutic failure and poor patient outcomes (6). A limited number of effective antifungals, drug-drug interactions, and drug toxicity exacerbate this issue. On the other hand, approximately half of all nosocomial infections are linked to the use of indwelling medical devices. *Candida* spp can attach, adhere, and form biofilms on abiotic surfaces such as medical devices (1,7,8). The biofilm's structure, as an impermeable barrier against antifungals, reduces the sensitivity of *Candida* isolates to antifungals, especially azoles.

Given the increased prevalence of *Candida* infections and the varying risk factors across regions, assessing antifungal susceptibility patterns of *Candida* spp. and pathogenesis factors, such as biofilm formation, allows for predicting the prevalence of fungal infections and for providing appropriate treatment protocols (9,10).

2. Objectives

This study aimed to identify *Candida* species from clinical samples and to assess the antifungal susceptibility patterns and biofilm-forming ability.

3. Methods

3.1 Study Design

This study was cross-sectional and descriptive, conducted on 100 *Candida* isolates obtained from culturing various clinical samples (blood, urine, body fluids, etc.) that were identified as *Candida* spp. in the microbiology laboratory at Imam Reza Hospital, Birjand, Iran, from December 2020 to March 2022. The following formula was used to calculate the sample size

based on the prevalence of *Candida* species, according to a previous study:

$$N = (Z_{1-\alpha/2})^2 P(1-P) / (\delta)^2$$

$$Z = 1.96, P=0.93, \alpha=0.05, \delta= 0.2$$

The standard strains of *Candida albicans* (ATCC 10231), *Candida glabrata* (ATCC 2001), *Candida Parapsilosis* (ATCC 22019), and *Candida tropicalis* (ATCC 20962) were also used to identify *Candida* isolates.

3.2 Participants

Our study population consisted of *Candida* isolates from the mycology archive of the Faculty of Medicine, collected during a comprehensive screening program for the elderly in Birjand in the summer of 2022, with ethics code (IR.bums. REC.1398.257). The *Candida* isolates used in the present study were collected from oral swab cultures of elderly participants in the screening program and are kept in the mycology archive of the Faculty of Medicine.

These isolates were collected from individuals over 60 years of age during oral and dental examinations using a swab. The isolates that were considered positive in terms of colony count on culture medium in the microbiology laboratory (cfu/ml>10⁵) were considered (regardless of clinical conditions).

Individual's refusal to participate in the research project.

3.3 Scales

3.3.1 Culture and Phenotypic Identification of *Candida* Isolates: The isolates were cultured on CHROM agar (Becton Dickinson, Germany) and incubated at 37°C for 24-48 h to identify phenotypic and morphological characteristics (11,12).

3.3.2 Molecular Identification: The previously described DNA extraction method was used with some modifications (13). In brief, fresh colonies were suspended in distilled water. Phenol and chloroform were added to the suspension, and the mixture was then centrifuged. The supernatant was transferred to a clean tube, ethanol was added, and the mixture was chilled. The sample was centrifuged to precipitate the DNA. Finally, the precipitated DNA was dissolved in distilled water, washed with ethanol, and stored at low temperature (14,15). The extracted DNA was used as a template in a polymerase chain reaction (PCR) reaction at an appropriate dilution

3.3.3 Polymerase Chain Reaction (PCR) Condition: In this study, PCR was performed using primers specific to *Candida* species, previously designed by Aratefar (2019) (13). The primers were obtained from the National Center for Biotechnology Information (NCBI) nucleotide database

(<https://www.ncbi.nlm.nih.gov/nucleotide/>). Their sequences underwent Basic Local Alignment Search Tool analysis and confirmation on NCBI. Sinacolon Company (Tehran, Iran) was responsible for synthesizing and shipping the primers. The sequences of the primers used in this study were shown in Table 1. The Act1 gene is the internal control. The PCR was optimized in a final volume of 25 μ L as follows: the mixture was prepared with 10 μ L of master mix (DNA biotech, Iran), 0.25 μ L of each primer, 2.5 μ L of each DNA template (14,15). Using diethyl pyrocarbonate water, the final volume of the mixture was adjusted to 25 μ L. The PCR thermal cycling condition was as

follows: initial denaturation at 95°C for 5min, followed by 35 cycles of incubation at 95°C for 45sec, 58°C for 45sec, and 72°C for 45sec. and finally 72°C for 7min as final extension. The PCR was carried out on a thermal cycler (PEQLAB, Germany). *Candida albicans* (ATCC 10231), *Candida glabrata* (ATCC 2001), *Candida tropicalis* (ATCC 20962), and *Candida Parapsilosis* (ATCC 22019) were used as the quality control strains.

Using agarose gel (1.2%) and gel documentation system (Bio Rad, USA), amplicons were performed to identify the species by discrimination of amplicon sizes (Table 1).

Table 1: Primer of Genes Used in This Study

Primers Name*	Sequences (5'→3')	Amplicons	References
C.alb	F-5'AGATTATTGCCATGCCCTGAG ^{3'} R ^{5'} CCATGTCGAACGTAGCGTATGC ^{3'}	606bp	22
C.gal	F ^{5'} ACCGTGCTTGCCCTCTACA ^{3'} R ^{5'} GACATCTGAGCCTCGTCTGA ^{3'}	212bp	22
C.tr	F ^{5'} AGAACAAGAAAACAGTGAAGCAA ^{3'} R ^{5'} CCATGTCGAACGTAGCGTATGC ^{3'}	126bp	22
C.par	F ^{5'} TACACCAAGCGACTCAGC ^{3'} R ^{5'} ACCAGCTGCTTTGACTTG ^{3'}	490bp	22
C.kr	F ^{5'} GCGTGTGCCATCCAATG ^{3'} R ^{5'} CAGGAGAATTGCTGTTCCC ^{3'}	1159bp	22
C.dub	F ^{5'} GTCGGACATATACCTCCAATC ^{3'} R ^{5'} CCATGTCGAACGTAGCGTAT ^{3'}	718bp	22

*C.alb: *C. albicans*; C.gal: *C. glabrata*; C.tr: *C. tropicalis*; C.par: *C. parapsilosis*; C.kr: *C. krusei*; C.dub: *C. dubliniensis*.

3.3.4 Antifungal Susceptibility Assays: Antifungal susceptibility assays for *Candida* isolates were performed using the broth microdilution technique according to Clinical and Laboratory Standards Institute (CLSI) M27-A3 recommendations. Identified isolates were tested against a suite of antifungals, including fluconazole, voriconazole, clotrimazole, itraconazole, and amphotericin B (provided by Sigma-Aldrich, Canada). The procedure was executed in 96-well microtiter plates. Antifungal dilutions were serially prepared, followed by the addition of 100 μ L of RPMI 1640 medium containing incremental drug concentrations to the wells. Thereafter, wells were inoculated with 0.5 - 2.5 $\times 10^3$ CFU/mL of yeast suspension. Sealed plates underwent incubation at 35 °C for 24-48 hours. The evaluated concentration spectra ranged from 64–0.125 μ g/mL for fluconazole to 16–0.03 μ g/mL for amphotericin B, itraconazole, voriconazole, and clotrimazole. Each *Candida* isolate was assayed in duplicate for each antifungal. Lastly, *Candida albicans* (ATCC 10231), *Candida glabrata* (ATCC 2001), *Candida tropicalis* (ATCC 20962), and *Candida Parapsilosis* (ATCC 22019) were used for quality control purposes. Finally, susceptibility

outcomes were interpreted according to the CLSI M-27 (S4) standard (Table 2) (16).

Table 2: The Antifungal Susceptibility Interpretations (μ g/mL) Described in Clinical and Laboratory Standards Institute (CLSI) Document M27-A3

Antifungal	Susceptibility Interpretations (μ g/ml)		
	Susceptible	Dose dependent	Resistant
Fluconazole	≥ 2	4	≤ 8
Clotrimazole	$0.12 \geq$	-	≤ 1
Voriconazole	$0.12 \geq$	-	≤ 1
Itraconazole	$0.12 \geq$	-	≤ 1
Amphotericin B	≥ 2	-	≤ 2

3.3.5 Quantitative Evaluation of Biofilm Production: The colorimetric microtiter plate technique (17) was utilized to assess biofilm production. Specifically, yeast suspensions standardized to 0.5 McFarland units were dispensed into triplicate wells. The microplate was incubated at 32°C for 24 hours. Following this phase, wells were decanted and rinsed three times with 300 μ L of isotonic saline. After ambient air-drying, biofilms were immobilized by adding 300 μ L of methanol for 30

minutes. Wells were then decanted and air-dried. Subsequently, 150 µL of 0.1% (w/v) crystal violet dye was applied, followed by a 5-minute incubation, then rinsed with distilled water at the faucet. Finally, 150 µL of 33% (v/v) glacial acetic acid was added per well, and absorbance readings were obtained using an ELISA spectrophotometer (Stat Fax, 2000; Germany) at 360 nm. Biofilm density was interpreted according to:

OD_C ≤ OD_{CN} :without biofilm formation
 OD_C < OD_C ≤ 2 × OD_C :weak biofilm formation
 2 × OD_C < OD_C ≤ 4 × OD_C :moderate biofilm formation
 4 × OD_C < OD_C :strong biofilm formation

3.4 Data Collection

In this study, *Candida* species were determined and genotyped by PCR, and the sensitivity of *Candida* isolates to nystatin, amphotericin B, and fluconazole was assessed using the broth microdilution method according to the CLSI protocol. Demographic information, including age, gender, antibiotic use, diabetes, and occurrence of oral lesions, was collected through a checklist for each patient.

3.5 Data Analysis

The data were analyzed by descriptive statistics, chi-square test, and Spearman's correlation using SPSS software (version 16.0). In all statistical analyses, $P < 0.05$ was considered statistically significant.

3.6 Ethical consideration

In the present study, after obtaining approval from the Ethics Committee of Birjand University of Medical Sciences, Birjand, Iran (IR.BUMS.REC.1401.251), the patient demographic characteristics (age, history of infection, symptoms, diabetes, etc.) were collected. It was recorded on a checklist by the researcher using information from the patients' medical records.

4. Results

In this present study, the average age ($\pm$ SD) of patients was 48.13 ± 17.23 years. Table 3 presents the demographic characterization.

The results demonstrated that *Candida* isolates predominated, with *C. albicans* (48/100), followed by *C. glabrata* (34/100). Additionally, two cases were identified as mixed infections (*C. albicans* with *C. glabrata*) by multiplex PCR. Other species identified include *C. krusei* (1/100), *C. tropicalis* (5/100), *C. parapsilosis* (1/100), and *C. dubliniensis* (9/100) (Figure 1).

The pattern of antifungal susceptibility is as follows: *C. albicans* was 81.25% resistant to fluconazole and 100% susceptible to amphotericin B. *C. glabrata* had equal sensitivity to the two azole drugs, fluconazole and

clotrimazole (26.47% and 73.52%, respectively), and, on the other hand, 70.58% were resistant to amphotericin B. The *Candida parapsilosis* isolate was susceptible to all antifungals. *C. krusei* was resistant to all azoles but susceptible to amphotericin B. Both *C. tropicalis* and *C. dubliniensis* exhibited susceptibility patterns to the antifungals studied. Table 4 presents the antifungal pattern of *Candida* isolates. The statistical analysis showed significant indifference in antifungal susceptibility patterns between *C. albicans* and *C. glabrata* isolates ($P < 0.001$).

Figure 1: Frequency (%) of *Candida* spp. Isolates




Table 3: Characterization and Distribution of *Candida* spp. Isolates

Demographic Factors		Frequency
Gender	Male	36
	Female	64
Inpatient department	Outpatient	48
	Surgery	9
	Infectious	1
	Obstetrics and Gynecology	5
	Internal Medicine (Male)	2
	Pediatrics	-
	ICU*	35
Sample	Urine	53
	Sputum	3
	BAL*	28
	Wound	12
	Vaginal secretion	1
	Body fluid	2
	Discharge from the hospital	1

*ICU: intensive care unit; ** BAL: Bronchoalveolar lavage

The results from examining biofilm formation in *Candida* isolates showed that the majority of isolates have a moderate ability to form biofilms (Table 5). According to the results, among *Candida* species, isolates of *C. albicans*, *C. glabrata*, and *C. dubliniensis* have shown the greatest ability to form biofilms at a moderate level. However, Strong biofilm formation

was observed in isolates of *C. albicans*, *C. glabrata*, and *Candida tropicalis*. The chi-square test was used to compare biofilm-forming ability between *C. albicans*

and *C. glabrata* isolates. Analysis of the results showed no significant difference in biofilm formation ability between *C. albicans* and *C. glabrata* isolates ($P = 0.91$).

Table 4: Antifungal Susceptibility Testing of *Candida* spp.

Species	Antifungal Agent	MIC ($\mu\text{g/mL}$)			Susceptibility No. (%)		P. value*
		Rang	50%	90%	Susceptible	Resistance	
<i>C. albicans</i> N= 48	Fluconazole	$\leq 8 - \geq 32$	16	32	9(18.75)	34(81.25)	>0.001
	Clotrimazole	$\leq 2 - \geq 8$	8	16	10(20.83)	38(79.16)	
	Voriconazole	$\leq 0.5 - \geq 8$	8	16	15(31.25)	33(68.75)	
	Itraconazole	$\leq 0.2 - \geq 4$	2	4	22(45.83)	26(45.16)	
	Amphotericin B	$\leq 0.125 - \geq 1$	0.5	1	48(100)	-	
<i>C. glabrata</i> N=34	Fluconazole	$\leq 2 - \geq 32$	16	32	9(26.47)	25(73.52)	>0.001
	Clotrimazole	$\leq 2 - \geq 32$	8	16	9(26.47)	25(73.52)	
	Voriconazole	$\leq 0.5 - \geq 8$	4	4	11(32.35)	23(67.64)	
	Itraconazole	$\leq 0.2 - \geq 4$	2	4	16(47.05)	18(52.94)	
	Amphotericin B	$2 - \geq 8 \leq$	4	2	10(29.41)	24(70.58)	
<i>C. parapsilosis</i> N=1	Fluconazole	0.12	0.2	0.12	1(100)	-	-
	Clotrimazole	0.06	0.12	0.06	1(100)	-	
	Voriconazole	0.12	0.5	0.06	1(100)	-	
	Itraconazole	0.06	0.2	0.06	1(100)	-	
	Amphotericin B	0.06	0.2	0.06	1(100)	-	
<i>C. tropicalis</i> N=5	Fluconazole	$\leq 2 - \geq 32$	2	8	2(40)	3(60)	1.00
	Clotrimazole	$\leq 2 - \geq 32$	2	4	2(40)	3(60)	
	Voriconazole	$\leq 0.5 - \geq 4$	1	2	2(40)	3(60)	
	Itraconazole	$\leq 0.2 - \geq 4$	1	2	2(40)	3(60)	
	Amphotericin B	$2 - \geq 4 \leq$	0.5	0.12	2(40)	3(60)	
<i>C. krusei</i> N=1	Fluconazole	4	4	8	-	1(100)	-
	Clotrimazole	2	2	4	-	1(100)	
	Voriconazole	1	1	2	-	1(100)	
	Itraconazole	0.5	0.5	1	-	1(100)	
	Amphotericin B	0.5	0.5	0.25	1(100)	-	
<i>C. dubliensis</i> N=9	Fluconazole	$\leq 2 - \geq 32$	16	32	3(33.33)	6(66.66)	1.00
	Clotrimazole	$\leq 2 - \geq 32$	8	32	3(33.33)	6(66.66)	
	Voriconazole	$\leq 2 - \geq 8$	2	4	3(33.33)	6(66.66)	
	Itraconazole	$\leq 2 - \geq 8$	2	4	3(33.33)	6(66.66)	
	Amphotericin B	$2 - \geq 8 \leq$	2	4	3(33.33)	6(66.66)	

* Using Chi-square and t-test.

5. Discussion

To establish the frequency and species distribution of invasive infections in Birjand (South Khorasan, Iran), the results showed that the main *Candida* species identified from clinical samples was *C. albicans*,

followed by *C. glabrata*, which had a significantly higher prevalence among these isolates. The antifungal susceptibility pattern shows that *Candida* isolates exhibit varying susceptibilities. Therefore, *C. albicans* isolates are susceptible to amphotericin B (about 100%), whereas *C. glabrata* and *C. tropicalis* showed

significant resistance to amphotericin B (Table 4). In the study conducted by Khadka et al. (2020), a total of 100 *Candida* species were identified, with *C. albicans* as the predominant species, followed by *C. tropicalis* (18). Their findings showed reduced antifungal susceptibility to clotrimazole, fluconazole, and miconazole. However, in a study by Seyoum et al. (2020), the predominant species reported was *C. albicans*, and the highest antifungal susceptibility was observed with voriconazole (19). In another study by Hosseinpour et al. (2019), conducted on 156 urine samples, the most common *Candida* spp. identified was *C. albicans*, followed by *C. tropicalis*, and all isolates were susceptible to amphotericin B (20).

In recent decades, *Candida* species, particularly *C. albicans*, have emerged as formidable nosocomial pathogens. Differentiation of *Candida* spp. predominantly hinges upon biochemical profiling, germ tube induction assays, and macroscopic colony characteristics across varied culture substrates. Employing CHROMagar for *Candida* speciation, predicated on chromatic disparity, offers an expeditious, pragmatic, and robust modality for discerning clinically pertinent isolates compared with arduous traditional methodologies (21). In resource-limited developing economies, CHROMagar is a pragmatic phenotypic diagnostic modality superseding molecular methods. Notwithstanding, extensive empirical studies demonstrate an elevated prevalence of isolation of non-*albicans* *Candida* (NAC) taxa relative to *C. albicans*, thereby heralding the ascendance of NAC as consequential etiological agents. On the other hand, an increase in resistance to the azole group, as the first-line antifungal therapy, among *Candida* spp. has, in this regard, rendered the therapeutic strategy with azoles defective and recurrent (22,23). Due to the widespread use of azole for fluconazole, resistance to it has increased and is of serious concern. Azoles are cornerstone therapeutics for mycotic infections, exerting their efficacy by suppressing ergosterol biosynthetic pathways in the phospholipid constituents of the fungal plasmalemma. Alternatively, amphotericin B exerts antifungal activity by depleting ergosterol from membrane lipid raft domains, precipitating cytolysis, concomitant with the accumulation of reactive oxygen intermediates, thereby fostering oxidative injury, apoptotic cascades, and lethal cytotoxicity (24,25). Given the rising resistance to commonly used antifungals for treating fungal infections, especially candidiasis, we are concerned about the obsolescence of this class of antifungals. Therefore, the advance of a new generation of antifungal compounds is a research priority.

In this study, the assessment of biofilm formation

showed that most *Candida* species can moderate it. However, no significant relationship was observed among the various species. In a study by Marak et al. (2020), *C. albicans* was reported as the most main *Candida* species; they acknowledged that the majority of isolates could moderate biofilm formation (25). According to the study results, the capability of *Candida* isolates to form biofilms is a clear reason for the emergence of resistance to each of the drugs studied. Understanding the mechanisms of resistance and the biological drivers of its emergence is essential for advancing therapeutics, enhancing diagnostics, and implementing interventions to overcome and prevent resistance.

Table 5: Evaluation of Biofilm Formation by Various *Candida* spp.

<i>Candida</i> spp.	Biofilm Formation Type (%)		
	Week No. (%)	Moderate No. (%)	Strong No. (%)
<i>C. albicans</i> (n=48)	11(18.75)	28(54.32)	9(18.75)
<i>C. glabrata</i> (n=34)	7(20.58)	23(67.64)	6(17.64)
<i>C. parapsilosis</i> (n=1)	0	1(100)	0
<i>C. tropicalis</i> (n=5)	0	2(40.00)	3(60.00)
<i>C. krusei</i> (n=1)	0	1(100)	0
<i>C. dubliniensis</i> (n= 9)	0	9(100)	0

Therefore, the challenges of treating *Candida* infections are not only related to antifungal treatment protocols but also to eliminating pathogenic factors of the microorganism, including biofilm formation, and to developing rapid and accurate diagnostic methods. Consequently, the limited treatment options and the increasing prevalence of antifungal-resistant strains necessitate the development of novel antifungal compounds and novel treatment strategies. Therefore, it is suggested that, while periodically monitoring the prevalence of nosocomial fungal infections, future studies should focus on the design and synthesis of naturally derived antifungal agents with fewer side effects.

5.1 Conclusion

According to the present study, periodic and regional surveys of the prevalence of fungal infections, especially *Candida* infections, and monitoring the antifungal susceptibility patterns of identified isolates can be beneficial for treatment, selecting appropriate therapeutic protocols, and preventing the emergence of strains resistant to common antifungals. Hence, this requires the use of accurate laboratory techniques to detect the fungal agent causing the infection early.

Statements

Authors' Contribution: All authors contributed to the study design, FN and MHN. FN was involved in

the initial idea of the study. FN, MM, and MHN participated in the data collection process. FN was involved in the data analysis. MM, MHN, and FN contributed to the drafting of the manuscript. All authors have read and approved the content of the manuscript.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication. The data are not publicly available.

Ethical Approval: The Ethics Committee of Birjand University of Medical Sciences approved the research protocol (IR.BUMS.REC.1401.251)

Funding/Support: The present article is financially supported by the "Research Department of the Birjand University of Medical Sciences, Birjand, Iran.

Conflict of Interest: The authors declared no conflicts of interest.

References

- Pristov KE, Ghannoum MA. Resistance of *Candida* to azoles and echinocandins worldwide. *Clin Microbiol Infect*. 2019;25(7):792–798. [PMID: 30965100.] [DOI: 10.1016/j.cmi.2019.03.028]
- Ghasemi R, Rabiei MM, Lotfali E, Abolghasemi S, Ansari S. Candiduria: Prevalence, Identification of Isolated *Candida* Species and Trends in Antifungal Susceptibility in Hospitalized Patients. *Nov Biomed*. 2020;8(2):71–8. [DOI:10.22037/nbm.v1i1.26963]
- Xiao M, Chen SC, Kong F, Xu XL, Yan L, Kong HS, et al. Distribution and antifungal susceptibility of *Candida* species causing candidemia in China: An update from the CHIF-NET Study. *J Infect Dis*. 2020 Mar 16 (Supplement_2);221: 136–47. [PMID: 32176789.] [DOI: 10.1093/infdis/jiz573.]
- Waikhom SD, Afeke I, Kwawu GS, Mbroh HK, Osei GY, Louis B, et al. Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: Species identification and antifungal susceptibility of *Candida* isolates. *BMC Pregnancy Childbirth*. 2020;20(1): 266. [PMID: 32375724; PMCID: PMC7201979.] [DOI: 10.1186/s12884-020-02963-3.]
- Tsega A, Mekonnen F. Prevalence, risk factors and antifungal susceptibility pattern of *Candida* species among pregnant women at Debre Markos Referral Hospital, Northwest Ethiopia. *BMC Pregnancy Childbirth*. 2019 Dec 30;19(1):527. [PMID: 31888537; PMCID: PMC6937829.] [DOI: 10.1186/s12884-019-2494-1.]
- Soni S, Dube A, Verma A, Gupta K, Gupta J, Saini A, et al. Neurodynamics in patient with Alzheimer's disease during working memory task. *Sch J Appl Med Sci*. 2017;5(8):3257–63. [DOI: 10.36347/sjams.2017.v05i08.053]
- Deorukhkar SC, Roushani S. Identification of *Candida* species: conventional methods in the era of molecular diagnosis. *Ann Microbiol Immunol*. 2018;1(1):1002. [URL: <https://www.remedypublications.com/open-access/identification-of-candida-species-conventional-methods-in-the-era-of-molecular-diagnosis-775.pdf>]
- Fuller J, Dingle TC, Bull A, Shokoples S, Laverdière M, Baxter MR, et al. Species distribution and antifungal susceptibility of invasive *Candida* isolates from Canadian hospitals: results of the CANWARD 2011-16 study. *J Antimicrob Chemother*. 2019 Aug;74(Suppl 4):48–54. [PMID: 31505645.] [DOI: 10.1093/jac/dkz287.]
- Azeredo J, Azevedo NF, Briandet R, Cerca N, Costa AR, Desvaux M, et al. Critical review on biofilm methods. *Crit Rev Microbiol*. 2017 May;7 43(3):313–351. [PMID: 27868469.] [DOI: 10.1080/1040841X.2016.1208146.]
- Donlan RM. Biofilm Formation: A Clinically Relevant Microbiological Process. *Clin Infect Dis*. 2001 Oct 15;33 (8):1387–92. [PMID: 11565080.] [DOI: 10.1086/322972.]
- EIFeky DS, Gohar NM, El-Seidi EA, Ezzat MM, AboElew SH. Species identification and antifungal susceptibility pattern of *Candida* isolates in cases of vulvovaginal candidiasis. *Alexandria J Med*. 2016;52(3):269–77. [DOI: 10.1016/j.ajme.2015.10.001]
- Mahmoudi Rad M, Zafarghandi S, Abbasabadi B, Tavallaei M. The epidemiology of *Candida* species associated with vulvovaginal candidiasis in an Iranian patient population. *Eur J Obstet Gynecol Reprod Biol*. 2011 Apr;155(2):199–203. [PMID: 21194828.] [DOI: 10.1016/j.ejogrb.2010.11.022]
- Arastehfar A, Fang W, Pan W, Lackner M, Liao W, Badiie P, et al. YEAST PANEL multiplex PCR for identification of clinically important yeast species: stepwise diagnostic strategy, useful for developing countries. *Diagn Microbiol Infect Dis*. 2019 Feb ;93(2):112–9. [PMID: 30377018.] [DOI: 10.1016/j.diagmicrobio.2018.09.007]
- Taira CL, Okay TS, Delgado AF, Ceccon ME, de Almeida MT, Del Negro GM. A multiplex nested PCR for the detection and identification of *Candida* species in blood samples of critically ill paediatric patients. *BMC Infect Dis*. 2014 Jul;14(1):406. [PMID: 25047415; PMCID: PMC4223582.]

- [DOI: 10.1186/1471-2334-14-406.]
15. ZARE BM, Ghasemi F, Ghanbarzadeh N, Noferesti F, Nikoomeh F. Using Single Multiplex PCR Reaction to Identify Candida Species in Vaginal Isolates: Comparison between Phenotypic and Molecular Methods. *Infect Epidemiol Microbiol*. 2022;8(4):337–44. [DOI:10.1093/iem/8.4.337]
 16. Nikoomeh F, Roudbarmohammadi S, Khoobi M, Haghighi F, Roudbary M. Design and synthesis of mucoadhesive nanogel containing farnesol: investigation of the effect on HWP1, SAP6 and Rim101 genes expression of *Candida albicans* in vitro. *Artif Cells Nanomed Biotechnol*. 2019 Dec;47(1):64–72. [PMID: 30663419.] [DOI: 10.1080/21691401.2018.1543193.]
 17. Sriphanom C, Nuanmuang N, Saengsawang K, Amornthipayawong D, Kummasook A. Anti-fungal susceptibility and virulence factors of *Candida* spp. isolated from blood cultures. *J Mycol Med*. 2019 Dec;29(4):325–30. [PMID: 31447236.] [DOI: 10.1016/j.mycmed.2019.08.001.]
 18. Khadka S, Sherchand JB, Pokhrel BM, Parajuli K, Mishra SK, Sharma S, et al. Isolation, speciation and antifungal susceptibility testing of *Candida* isolates from various clinical specimens at a tertiary care hospital, Nepal. *BMC Res Notes*. 2017 Jun;10(1):218 [PMID: 28646915; PMCID: PMC5483268.] [DOI: 10.1186/s13104-017-2547-3]
 19. Seyoum E, Bitew A, Mihret A. Distribution of *Candida albicans* and non-*albicans* *Candida* species isolated in different clinical samples and their in vitro antifungal susceptibility profile in Ethiopia. *BMC Infect Dis*. 2020 Mar;20(1):231. [PMID: 32188422; PMCID: PMC7081544.] [DOI: 10.1186/s12879-020-4883-5.]
 20. Hoseinpour M, Rashki Ghalehnoo Z, Tadjrobehkar O. Antifungal Susceptibility of *Candida* Species Isolated from Admitted Patients with Candiduria in Amir Al-Momenin Hospital, Zabol. *J Jiroft Univ Med Sci*. 2019;5(2):75–86. [URL: <http://journal.jmu.ac.ir/article-1-241-en.html>]
 21. Yücesoy M, Marol S. Performance of CHROMAGAR *candida* and BIGGY agar for identification of yeast species. *Ann Clin Microbiol Antimicrob*. 2003 Oct;2(1):8. [PMID: 14613587; PMCID: PMC280667.] [DOI: 10.1186/1476-0711-2-8.]
 22. Rezaei H, Foroughi-Parvar F, Maghsood A, Fallah M, Saidijam M, Matini M. Prevalence of bacterial vaginosis and vaginal candidiasis in women presenting to healthcare centers of Hamadan City, West of Iran. *Pars J Med Sci*. 2022;15(2):17-23. (Persian). [DOI: 10.29252/jmj.15.2.17]
 23. Ahmad A, Khan AU. Prevalence of *Candida* species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. *Eur J Obstet Gynecol Reprod Biol*. 2009 May;144(1):68-71. [PMID: 19261369.] [DOI: 10.1016/j.ejogrb.2008.12.020.]
 24. Modiri M, Hashemi SJ, Ghazvini RD, Khodavaisy S, Ahmadi A, Ghaffari M, et al. Antifungal susceptibility pattern and biofilm-related genes expression in planktonic and biofilm cells of *Candida parapsilosis* species complex. *Curr Med Mycol*. 2019;5(4):35–42. [PMID: 32104742; PMCID: PMC7034785.] [DOI: 10.18502/cmm.5.4.1950.]
 25. Marak MB, Dhanashree B. Antifungal susceptibility and biofilm production of *Candida* spp. Isolated from clinical samples. *Int J Microbiol*. 2018 Oct;2018(1):7495218. [PMID: 30405717; PMCID: PMC6199855.] [DOI: 10.1155/2018/7495218.]